Swiss Re Tackles Longevity Drug Impact With Life Policy Advice
Metformin, traditionally used to manage type 2 diabetes, and rapamycin, an immunosuppressant developed for organ transplant recipients, are part of a growing list of substances being explored for anti-aging purposes, Swiss Re said. In some cases, the medications are being self-prescribed, the reinsurer said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Biogen Sees Potential in Combining Alzheimer's and Obesity Drugs
If Novo Nordisk A/S 's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy. 'As we look out over the next five years, we're probably going to see a treatment much like any other complex disease,' he said in an interview with Bloomberg News, meaning there will be 'different mechanisms of action that you need.'
Bloomberg
an hour ago
- Bloomberg
UK Primary Health Properties Fends Off KKR Bid for Landlord Assura
Primary Health Properties Plc has prevailed in the fiercely contested takeover battle for rival landlord Assura Plc, a watershed deal that saw shareholders reject a cash offer from private equity in favor of remaining invested in a UK public company. The transaction will create the UK's largest publicly traded health care landlord, bringing together PHP's £2.81 billion ($3.8 billion) portfolio with Assura's £3.1 billion of assets to create the country's eighth most valuable real estate investment trust by market capitalization.
Yahoo
3 hours ago
- Yahoo
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda
The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges include high therapy costs and resistance to current treatments. Major players investing in R&D include Novartis, Abbvie, and Bristol-Myers Squibb. Key terms: Global Multiple Myeloma Market, Multiple Myeloma Growth, Targeted Therapies, Immunotherapies, Market Expansion. Multiple Myeloma Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to Global Multiple Myeloma Market was valued at USD 21.78 billion in 2024 and is expected to reach USD 40.41 billion by the year 2033, at a CAGR of 7.11% during the forecast period from 2025 to 2033 The growth of the market is fueled by the increasing number of multiple myeloma cases, developments in targeted therapies, and the expanding use of immunotherapies. Increased oncology research, enhanced diagnostic methodologies, and the increasing availability of healthcare facilities are further adding to market growth. The therapies for multiple myeloma are chemotherapy, immunotherapy, target therapies, corticosteroids, and stem cell transplants. Increasing advancements in monoclonal antibodies and CAR-T cell therapy are enhancing outcomes among patients, and these therapies are becoming more popular globally. With increasing awareness of cancer and better diagnosis methods, multiple myeloma therapies are becoming increasingly popular in the U.S., Europe, and Asia-Pacific. Pharmaceutical industries are heavily investing in new drug development, and governments are also funding cancer research, further propelling treatment availability. Consequently, the multiple myeloma market continues to grow, bringing new hope to patients of Growth in the Multiple Myeloma Market Improvements in Targeted TherapiesThe emergence of targeted therapies like monoclonal antibodies and proteasome inhibitors has considerably enhanced treatment efficacy for multiple myeloma patients. These treatments have greater efficacy with less side effect than conventional chemotherapy. With continued research in immunotherapy and CAR-T cell therapy, more effective therapies are being made available, and patient survival is on the rise. Consequently, drug companies are investing heavily in drug development, further fueling market growth. Dec 2024, Merck reported that the FDA has accepted for filing the Biologics License Application for clesrovimab (MK-1654), a long-acting monoclonal antibody to help protect infants from RSV in their first RSV Prevalence of Multiple MyelomaThe worldwide prevalence of multiple myeloma is on the rise, especially among the elderly. Genetic susceptibility, exposure to toxic chemicals, and lifestyle changes are factors that lead to an increased incidence of the disease. As more and more cases are being diagnosed yearly, the need for effective treatment options is on the rise. This has driven governments and health organizations to invest more in multiple myeloma research and the availability of treatments, driving market growth. There were about 35,000 cases of MM in 2021 globally, with the most in China and Germany, with 47,003 and 32,010 cases, respectively. In 2021, Europe boasted the highest ASIR and ASPR, and North America the highest ASMR and Healthcare Spending and AwarenessRising healthcare spending in developed and emerging economies is contributing positively towards the multiple myeloma market. Governments and private bodies are initiating awareness campaigns and screening programs to encourage early detection and timely treatment. Patients now enjoy improved access to new therapies through reimbursement schemes and insurance coverage, also driving the adoption of treatments. With increasing numbers of hospitals and clinics incorporating advanced oncology treatments, the multiple myeloma market is set to see significant in the Multiple Myeloma Market Exorbitant Cost of TherapyImmunotherapies and targeted agents used in treating multiple myeloma are costly, hence unavailable to most patients, particularly those in developing areas. Bone marrow transplants and maintenance therapy costs further increase the burden. In spite of availability of reimbursement schemes in certain countries, affordability becomes a serious concern, limiting the growth of the Effects and Therapy ResistanceIn spite of the progress in treatment, patients tend to develop resistance to current therapies with time, which requires frequent modification of treatment regimens. Moreover, most therapies have serious side effects, such as infections, tiredness, and organ injury, which lower the quality of life for patients. These issues propel the necessity for ongoing research and innovation in treatment methods. Key Players Analyzed: Overview, Key Persons, Recent Developments, Product Portfolio, Revenue Novartis AG Abbvie Inc. Sanofi Johnson and Johnson Baxter International Inc. Pfizer Inc. Takeda Pharmaceutical Company Ltd Bristol-Myers Squibb Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $21.78 Billion Forecasted Market Value (USD) by 2033 $40.41 Billion Compound Annual Growth Rate 7.1% Regions Covered Global Key Topics Covered: 1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Multiple Myeloma Market6. Market Share Analysis6.1 By Drugs Types6.2 By Disease Types6.3 By End User6.4 By Country7. Drugs Types7.1 Chemotherapy7.2 Protease Inhibitors7.3 Monoclonal Antibody7.4 Others8. Disease Types8.1 Active multiple myeloma8.2 Smoldering multiple myeloma9. End User9.1 Hospitals9.2 Clinics9.3 Others10. Countries10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 United Arab Emirates11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Multiple Myeloma Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
